anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fluticasone Propionate DISKUS inhalation powder is a dry powder inhaler for oral inhalation. The active component of Fluticasone Propionate DISKUS 50 mcg, Fluticasone Propionate DISKUS 100 mcg, and Fluticasone Propionate DISKUS 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, 17-propionate and the following chemical structure: 

Fluticasone propionate is a white powder with a molecular weight of 500.6, and the empirical formula is C25H31F3O5S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. 

Fluticasone Propionate DISKUS is an orange plastic inhaler containing a foil blister strip. Each blister on the strip contains a white powder mix of micronized fluticasone propionate (50, 100, or 250 mcg) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins). After the inhaler is activated, the powder is dispersed into the airstream created by the patient inhaling through the mouthpiece.

Under standardized in vitro test conditions, Fluticasone Propionate DISKUS delivers 46, 94, and 229 mcg of fluticasone propionate from Fluticasone Propionate DISKUS 50 mcg, Fluticasone Propionate DISKUS 100 mcg, and Fluticasone Propionate DISKUS 250 mcg, respectively, when tested at a flow rate of 60 L/min for 2 seconds.

In adult subjects with obstructive lung disease and severely compromised lung function (mean FEV1 20% to 30% of predicted), mean peak inspiratory flow (PIF) through the DISKUS inhaler was 82.4 L/min (range: 46.1 to 115.3 L/min). In children with asthma aged 4 and 8 years, mean PIF through Fluticasone Propionate DISKUS was 70 and 104 L/min, respectively (range: 48 to 123 L/min). 

The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile.
The present invention relates in a first aspect to a method for the prediction of a survival rate of an individual or a very relevant health event selected from vascular disease, disorder or condition, including major cardiovascular disease, and renal failure within a predetermined time period or at a predetermined time end point, whereby an urine sample from the individual is analysed by GE-MS and based on the information of peptidome/proteome present in said urine, the survival rate of said individual or the very relevant health event within the predetermined time period or at a predetermined time end point is calculated. Further, the present invention applies a specific predetermined multidimensional classifier for calculating the survival rate or the very relevant health event. That is, the survival rate reflects the probability of future death within the predetermined time period or the predetermined time end point. The method includes in an embodiment artificial intelligence routine. The individuals analysed include individuals with pre-existing conditions as well as healthy individuals. Moreover, a computer implemented method for the prediction of the survival rate of an individual or the very relevant health event is provided as well as a computer readable medium or computer program product having computer executable instructions for performing the method according to the present invention.
Patients receive cisplatin or carboplatin IV over 30-60 minutes QW for 6 doses with concurrent IMRT and IGRT five days a week for 30-33 fractions in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, PET-CT, and/or chest x-ray during screening and follow-up. Patients may also undergo blood sample collection during follow-up.
Participants in the psychoeducation arm listen to TEDTalks audio recordings by experts on field-specific topics. Study participants are instructed to complete 10 minutes of TEDTalks twice per day for 14 days. Sessions were selected by the study team to be of interest to the public yet not include content on meditation, smoking, or content appearing to cue behavior change associated with smoking. Like the Mindfulness condition, participants in the Psychoeducation condition begin the practice the day after the baseline interview. Participants are told to listen at two separate times each day to maximize daily exposure with low time burden. Additionally, participants are instructed to listen with "full mindful attention and return attention to the audio when attention drifts" to match the Mindfulness instruction and emphasize the importance of sustaining attention for each 10-minute period. Participants have access to all sessions offered and are not restricted to a particular sequence.
The invention discloses a smoke cessation balsam which can strongly disturb and eliminate the dependence of nicotine produced through long time smoking. The balsam is mainly made of eighteen Chinese medical herbs such as mint, cinnamon, lemon, round cardamom, borneol, and so on as well as spice extracts, which are mixed with plant oil, oil immersion and lanoline. The invention has thick aroma, and disturbs and eliminates the dependence of nicotine produced through long time smoking by releasing the aroma, thereby causing the smoker to produce disgust for cigarettes, so that the craving for cigarette is decreased till disappeared so as to achieve the smoke cessation. The invention has a quick effect and is convenient. When wanting to have a cigarette, the invention is put below the nose for inhaling a plurality of times with deep breath, with about fifteen seconds for each time and multiple times for each day; the invention comes into effect after three to seven days in normal conditions. For these smokers having a great craving for cigarette and these smokers having a long smoking time, the balsam can be coated on the cigarette; and then the cigarette is smoked as usually, with a better effect.
Diazepam is a benzodiazepine derivative. The chemical name of diazepam is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. It is a colorless to light yellow crystalline compound, insoluble in water. The empirical formula is C16H13ClN2O and the molecular weight is 284.75. The structural formula is as follows:

Diazepam is available for oral administration as tablets containing 2 mg, 5 mg or 10 mg diazepam. In addition to the active ingredient diazepam, each tablet contains the following inactive ingredients: calcium stearate, colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate and microcrystalline cellulose with the following dyes: 5-mg tablets contain D&C Yellow #10 aluminum lake; 10-mg tablets contain FD&C Blue #1 aluminum lake. Diazepam 2-mg tablets contain no dye.
Rationale: Auditory hallucinations (AH) are a symptom of several psychiatric disorders, such as schizophrenia. In the majority of patients, these AH respond well to antipsychotic medication. Yet, a significant minority continues to experience frequent AH despite optimal pharmacotherapy and AH severely decrease quality of life in these patients. The number of alternative treatment options for this medication resistant group is currently low and most of them focus on coping with the hallucinations. Transcranial direct current stimulation (tDCS), in contrast, is a safe, non-invasive technique that is able to directly influence cortical excitability through the application of very low electric currents. This technique has only a few transient side-effects and is cheap and portable. To date, only one randomized controlled trial has been published, suggesting high efficacy of tDCS for the treatment of medication-resistant AH in a relatively small sample. We aim to replicate and extend these findings by investigating the efficacy of this technique in a larger sample.
According to an aspect of an embodiment, a method may include obtaining, at a mobile biometric-data hub, a first biometric reading of a user. The method may also include, based on the first biometric reading, associating the mobile biometric-data hub with the user. The method may also include wirelessly receiving, at the mobile biometric-data hub, a second biometric reading from a biometric sensor distinct from the mobile biometric-data hub. The method may also include determining that the second biometric reading is of the user. The method may also include, based on the second biometric reading being of the user and based on the association between the mobile biometric-data hub and the user, tagging the second biometric reading with an identifier of the user. The method may also include communicating the tagged second biometric reading from the mobile biometric-data hub to a network-attached device.
FIELD: medicine, surgery, dermatology, cosmetology, veterinary science. SUBSTANCE: method involves dissolving trinitrotoluene in dimethylsulfoxide at the room temperature, not below. Process is carried out up to appearance of dark-blue color. Mixture is mixed with filling agent - acid solution, mainly, powder-like in ethanol, glycerol is added followed by filtration. Initial alcohol concentration in final product must be 70%, not less. By another variant process of trinitrotoluene dissolving in dimethylsulfoxide is carried out at constant temperature at the range 30-70 C. Agent can be used for prophylaxis and treatment of bacterial complications. EFFECT: improved method of preparing. 15 cl
PROBLEM TO BE SOLVED: To obtain a cosmetic, excellent in UV-A absorptivity, excellently familiar with skin, capable of manifesting an excellent preservation stability by formulating a benzalhydantoin-based ultraviolet absorber having extremely small solubility. SOLUTION: This cosmetic is obtained by formulating the powder of a 5-(3,4- dialkoxybenzal)hydantoin of the formula (R<1> and R<2> are each a 1-3C alkyl) and/or the power obtained by carrying out a coating treatment of a power for cosmetics (e.g. a pigment) with the compound of the formula as an ultraviolet absorber. The compound of the formula can be obtained by condensing a 3,4-dialkoxybenzaldehyde with hydantoin using a basic catalyst. The powder formulated as an ultraviolet absorber preferably has an average particle diameter of 0.001-100 μm, and the mixing amount of the powder is preferably 0.01-10 wt.%. As a result, the cosmetic having no problem of crystal precipitation, etc., even if preserved for a long term, and excellent in functionality and form stability is expected.
Amevive® has been shown to be a safe and effective agent in the treatment of psoriasis but may prove useful in treating atopic dermatitis at a dose of 15mg IM every week for 12 weeks. Unlike other "biologics" for the treatment of skin diseases, the use of alefacept is not associated with increased infection, congestive heart failure, demyelinating disorders or lupus- like syndromes.
Zolpidem is a hypnotic drug which at sub-sedative doses has been shown to improve both motor and cognitive deficits in stroke, dementia and Parkinson's. This has led to the hypothesis that low-dose zolpidem will be effective in early-stage Parkinson's, delaying the need for dopamine-replacement interventions, as an adjunct therapy, and in late-stage Parkinson's where current interventions are ineffective for motor and cognitive decline. At present, the symptoms of late-stage Parkinson's are the most debilitating and the least well-controlled. Here, the investigators propose a placebo controlled double-blinded proof-of-concept study in order to determine the benefits of taking low-dose zolpidem in late-stage Parkinson's. The study will take place over 12 months. 28 participants, diagnosed with Parkinson's for at least 5 years will be recruited; 14 participants will take zolpidem (5 mg) and 14 placebo, each morning for 4 days. In the clinic (day 1) clinical assessments will include the motor III of the Unified Parkinson's Disease Rating Scale (UPDRS) and cognitive verbal fluency tasks which will be conducted at baseline and 1 hour following drug administration. Each participant will then be issued with a smartphone with application to objectively test their motor performance 4 times a day, over the next six days (3 days on drug, 3 days off drug). This study will provide the necessary data on drug efficacy in order to design a phase II clinical trial for the use of low-dose zolpidem in late-stage Parkinson's.
In a prospective, open-label, single-arm, multicenter clinical study, efficacy, safety and pharmacokinetics of ASCENIV were evaluated in 59 subjects with PI ( See Clinical Studies [14]). Serum concentrations of total IgG were measured in 30 subjects (four subjects, ages 7 to 16 years and 26 subjects from 17 to 74 years) following the seventh infusion for subjects on a 4-week dosing interval and the ninth infusion for subjects on a 3-week dosing interval. The dose of ASCENIV used in these subjects ranged from 291 mg/kg to 760 mg/kg. After the infusion, blood samples were taken until Day 28 after infusion for the 4-week dosing interval and until Day 21 after infusion for the 3-week dosing interval. Table 4 summarizes the Total IgG Pharmacokinetic Parameters of ASCENIV, based on serum concentration of total IgG. The mean ± SD half-life of ASCENIV was 28.5 ± 4.4 days for subjects on a 3-week dosing interval and 39.7 ± 11.6 days for subjects on a 4-week dosing interval for the 30 subjects in the pharmacokinetic subgroup. Although no systematic study was conducted to evaluate the effect of sex on the pharmacokinetics of ASCENIV, based on the small sample size (11 males and 19 females) the pharmacokinetics of ASCENIV was comparable between males and females. In adolescents, the pharmacokinetics of ASCENIV was comparable with adults. There were insufficient PK data in children younger than 12 years.
PROBLEM TO BE SOLVED: To obtain a nutritive composition having bone strengthening effect and hypotensive effect. SOLUTION: This composition contains 0.3-0.5 pt.wt. of magnesium and 0.25-1 pt.wt. of phosphorus based on 1 pt.wt. of calcium. This invention also relates to foods and beverages, pharmaceuticals and feeds containing calcium, magnesium and phosphorus at ratios adjusted to the above ranges. Inorganic compounds, organic compounds or natural materials containing calcium, magnesium and phosphorus as mineral components are used as the sources for calcium, magnesium and phosphorus.
Disclosed herein is a system for facilitating administration of a pharmaceutical product. Accordingly, the system may include at least one sensor, a storage device, a processing device, and a Mobile Administration Interlocking Device (MAID). Further, the at least one sensor may be disposed on body of a user. Further, the at least one sensor may be configured for generating at least one physiological data associated with the body. Further, the storage device may be configured for storing at least one dosage data. Further, the at least one dosage data may be prescribed by a medical professional. Further, the processing device may be communicatively coupled with the at least one sensor. Further, the processing device may be communicatively coupled with the storage device. Further, the MAID may be configured for provisioning the pharmaceutical product to the user. Further, the MAID may be communicatively coupled with the processing device.
* Stop Tri-Sprintec ®if an arterial thrombotic event or venous thromboembolic (VTE) event occurs. 
  * Stop Tri-Sprintec ®if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately [see Adverse Reactions ( 6.2)] . 
  * If feasible, stop Tri-Sprintec ®at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization. 
  * Start Tri-Sprintec ®no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. 
  * The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.
  * Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). This risk increases with age, particularly in women over 35 years of age who smoke.
  * Use COCs with caution in women with cardiovascular disease risk factors.
The present invention relates to a novel pharmaceutical composition of a self-emulsifying matrix preparation, which is a preparation for transmucosal or transdermal absorption in which a self-emulsifying drug delivery system is grafted to a polymeric matrix preparation. For this, fatty alcohol, fatty acid or their derivatives of 6 to 20 carbon atoms having a drug absorption-accelerating action through the skin or mucous membrane is used as an oil phase. Also, to increase the drug content in the matrix, a liquid phase material having a boiling point of 100° C. or more is used as a solution adjuvant. Using such materials, the self-emulsifying system with a surfactant is prepared. A hydrophilic or hydrophobic polymer is added and dissolved in the self-emulsifying system, and the resulting mixture is dried to prepare the matrix preparation containing the self-emulsifying system. The self-emulsifying matrix preparation thus prepared maintains a constant drug-releasing rate during its application period by virtue of its excellent stability and exhibits an extraordinarily high skin-absorption rate.
The erector spinae plane block (ESPB) is a less invasive, safer, and technically easy alternative procedure to conventional neuraxial anesthetic techniques. In contrast to common neuraxial techniques such as paravertebral and epidural injections, the ESPB targets an interfascial plane which is far from the spinal cord, root, and pleura. First applied to thoracic neuropathic pain, currently ESPB is being applied to postoperative pain control and includes variable clinical situations. In the abdomen and thoracic wall, thoracic ESPB can be applied for pain control after cardiac surgery, video-assisted thoracic surgery, laparoscopic cholecystectomy, and thoracotomy. Recently, favorable postoperative pain control after lumbar spinal or lower limb surgeries has been reported with lumbar ESPB. In addition, ESPB has also been used for chronic pain conditions in the upper and lower extremities. To investigate the possible mechanism of action of the ESPB, many previous studies have focused on examining the physical spread of the injected agent. Commonly, contrast dye injections in human cadavers have been utilized to assess the spread level. Physical spread level was determined using various methods including direct dissection or sectioning, computed tomography (CT), thoracoscopic inspection, or magnetic resonance imaging (MRI) with radiocontrast injection. Apart from human cadaver studies, physical spread level has been evaluated in alive patients using a variable volume of local anesthetics mixed with radiocontrast. However, these studies are limited by the small number of included patients.
INTRODUCTION: Pain might be approached from a biomedical or biopsychosocial perspective. There is a lack of research on the attitudes and beliefs about pain among physiotherapy students. In this context, the Pain Attitudes and Belief Scale for Physiotherapists (PABS-PT) is an instrument widely used from a clinical and educational perspective, but its psychometric properties have not yet been tested in a student-based population.
OBJECTIVE: To develop the Spanish version of the PABS-PT scale and to assess its psychometric properties among students in physiotherapy.
METHODS: The study was carried out among 103 students in their final years of academic studies in the Degree in Physiotherapy in the University of Murcia (Spain). Sociodemographic and PABS-PT related variables were collected. The instrument was translated into Spanish and tested through factor analysis, internal consistency, test-retest reliability, and known-groups validity. The 95% minimal detectable change of the instrument was also calculated.
RESULTS: The factor analysis revealed two factors within the instrument: Biomedical (9 items) and Biopsychosocial (7 items) factors, with Cronbach's alpha values of 0.730 and 0.708, respectively. The Intraclass Correlation Coefficient (3,2) was 0.851 for the Biomedical factor and 0.699 for the Biopsychosocial factor. The minimal detectable changes (95% CI) for the Biomedical and Biopsychosocial factors were 6.01 and 5.56, respectively. The pre-specified hypothesis for the known-groups validity test was met and revealed large effect sizes (d = 1.24).
CONCLUSION: The Spanish version of the instrument PABS-PT-SP covers two factors. It shows satisfactory psychometric properties and it is therefore an effective framework to discriminate between the biomedical and/or biopsychosocial thoughts and attitudes toward pain in physiotherapy.
The invention discloses a pomegranate skin care product and a preparation method thereof and relates to the field of daily chemicals. The pomegranate skin care product comprises 0.1-3 parts of carbomer, 1-5 parts of glycerin, 1-15 parts of polyethylene glycol, 0.1-3 parts of triethanolamine, 1-20 parts of pomegranate extract, 1-5 parts of purple eggplant extract and 2-8 parts of longan extract. The purple eggplant extract contains delphinidin and solamargine and can restore the skin against loss of collagen and elastin caused by light injury and burn and inflammations caused by pore expansion and ultraviolet. Purple eggplant is a common vegetable, is widely planted and is low in cost. The longan extract is leaching solution of longan shells and/or longan seeds, the raw materials are easy to obtain, and waste is turned into wealth. Effective components in the pomegranate extract, the purple eggplant extract and the longan extract can work in coordination with each other, and the goals of scavenging free radicals, restoring damaged skin and recovering skin functions are achieved better.